SRX Global Inc. Form 8-K Summary
Business Context and Reporting Period
SRX Global Inc. (formerly SRx Health Solutions, Inc.), a Delaware corporation, filed this Current Report on Form 8-K on July 27, 2026. The company is incorporated in Delaware and maintains its principal executive offices in Palm Beach, Florida. Its common stock trades under the symbol SRXH on NYSE American.
Key Financial Metrics and Transaction Details
This filing reports a specific capital raise event rather than periodic financial performance metrics such as revenue, profit, or operating cash flow. The filing details an Additional Closing under a Securities Purchase Agreement dated March 16, 2026.
- Transaction Date: July 27, 2026
- Securities Issued: 4,340 shares of Series B Convertible Preferred Stock and 284,156 Warrants to purchase Common Stock.
- Aggregate Proceeds: Approximately $3.472 million paid in cash.
- Warrant Adjustment: The warrant count reflects a 60-for-1 reverse stock split effective July 2, 2026.
Material Changes and Prior Period Comparison
The filing describes the completion of the second tranche of a private placement initiated on March 16, 2026.
- Initial Closing (March 16, 2026): The company raised approximately $4.528 million by issuing 5,660 shares of Series B Preferred Stock and 22,237,666 Warrants.
- Current Closing (July 27, 2026): The company raised approximately $3.472 million by issuing the remaining 4,340 shares of Series B Preferred Stock and adjusted Warrants.
- Total Placement Capacity: The agreement allowed for up to $8.0 million in aggregate proceeds. The combined proceeds from both closings total approximately $8.0 million ($4.528 million + $3.472 million), indicating the full utilization of the agreement.
Guidance, Risks, and Unusual Items
The filing does not contain forward-looking guidance, management commentary on operations, or specific risk factors beyond standard securities law disclosures.
- Regulatory Status: Securities were sold unregistered in reliance on Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D.
- Restrictions: The securities may not be offered or sold in the United States absent registration or an applicable exemption.
- Unusual Items: The filing notes a 60-for-1 reverse stock split that took effect on July 2, 2026, which adjusted the number of warrants issued in this closing.
Key Facts for Investor Verification
- Verify the total capital raised ($8.0 million) against the company's current cash position and liquidity needs.
- Confirm the terms of the Series B Convertible Preferred Stock, including conversion rates and liquidation preferences, which are not detailed in this summary.
- Review the impact of the 60-for-1 reverse stock split on the company's share count and market capitalization.
- Check for any subsequent filings regarding the registration rights of the investors or the exercise of the warrants issued.